Fitness Conferred by BCR-ABL Kinase Domain Mutations Determines the Risk of Pre-Existing Resistance in Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is the first human malignancy to be successfully treated with a small molecule inhibitor, imatinib, targeting a mutant oncoprotein (BCR-ABL). Despite its successes, acquired resistance to imatinib leads to reduced drug efficacy and frequent progression of disease. Unde...

Descripción completa

Detalles Bibliográficos
Autores principales: Leder, Kevin, Foo, Jasmine, Skaggs, Brian, Gorre, Mercedes, Sawyers, Charles L., Michor, Franziska
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3225363/
https://www.ncbi.nlm.nih.gov/pubmed/22140458
http://dx.doi.org/10.1371/journal.pone.0027682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3225363/
https://www.ncbi.nlm.nih.gov/pubmed/22140458
http://dx.doi.org/10.1371/journal.pone.0027682

Ejemplares similares